Group 1: Automotive Industry - Changan Automobile plans to invest 225 million yuan to enter the robotics sector, establishing Changan Tian Shu Intelligent Robot Technology Co., Ltd. with a total registered capital of 450 million yuan [2][3] - The new company aims to leverage humanoid robot technology to drive Changan's strategic transformation from a traditional automaker to an "intelligent technology ecosystem platform" [3] - The humanoid robotics sector is seen as a significant growth opportunity, with Changan's strong position in data accumulation, supply chain integration, and financial strength potentially leading to enhanced valuation and business synergies in the long term [3][4] Group 2: Vaccine Industry - The vaccine industry continues to see breakthroughs in internationalization and research, with companies like Kangtai Biotech and Zhifei Biological making significant progress in vaccine development [6][9] - The demand for flu vaccines is expected to rise, especially among high-risk groups, as the seasonal flu activity increases [8][9] - The vaccine sector is experiencing structural differentiation, with a focus on innovation and international expansion as key strategies for long-term growth [14][15] Group 3: Medical Services - The medical services sector has shown resilience, with a recent increase in demand driven by seasonal illnesses, despite ongoing cost control pressures from insurance policies [21] - The State Council's initiative to promote provincial-level medical insurance coordination is expected to enhance the efficiency of healthcare resources and provide structural opportunities for the medical industry [19][20] - Investment recommendations focus on high-growth companies in the pharmaceutical outsourcing and consumer healthcare sectors, indicating a positive outlook for the medical services industry [21]

证券研究报告 2025 年 12 月 1 日 湘财证券研究所 行业研究 家电行业周报 估值洼地，龙头业绩确定性强 相关研究： 核心要点： ❑ 板块持续跑输大盘，在市场风格切换时有望受益 行业评级：增持（首次覆盖） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -3.5% 12.8% 5.0% 绝对收益 -3.5% 18.0% 14.7% 注：相对收益与沪深 300 相比 分析师：张弛 证书编号：S0500525110001 Tel：17621838100 Email：zc08241@xcsc.com 分析师：李育文 证书编号：S0500523060001 Tel：021-50295328 Email：liyw3@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 年初至今家电行业涨幅较低，仅为+7.82%，在 31 个申万一级行业中仅仅 排名第 21 名，未能跑赢同期沪深 300 指数（+15.04%）。板块内部来看， 年初以来的主要上涨来自家电零部件子行业，空调（+0.15%）、冰洗（-3.98%） 等子行业基本停滞不前。而板块内部部分龙头公司市场份额稳步提升，现 ...

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

证券研究报告 2025 年 11 月 30 日 湘财证券研究所 核心要点： 行业研究 证券行业周报 两融余额维持高位，日均交易量小幅回落 相关研究： 1.《行业周报：成交额小幅回落， 融资余额持续增长》 2025.10.19 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -3 -12 -18 绝对收益 -7 -11 -2 -20% -10% 0% 10% 20% 30% 2024/11/28 2025/1/28 2025/3/28 2025/5/28 2025/7/28 2025/9/28 2025/11/28 沪深300 证券Ⅱ(申万) 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 ❑ 市场回顾：板块 PB 估值回落至 33%分位数 根据 Wind 数据，上周（11.24-11.28）上证指数上涨 1.4%，沪深 300 指数 上涨 1.6%，创业板指上涨 4.5%。申万非银金融 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - Vaccine companies are achieving breakthroughs in internationalization and research and development, while the pressure for winter epidemic prevention continues to highlight the need for effective measures [4][9] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges, but the long-term outlook remains positive due to supportive policies, increasing demand, and technological advancements [9][28] Summary by Sections Recent Developments - Zhifei Biological's subsidiary obtained a U.S. patent for an RSV vaccine, marking a significant step in its international market strategy [3] - Watson Bio's subsidiary received a marketing license for a 13-valent pneumonia vaccine in Egypt, enhancing its international presence [3] - Wuhan Institute of Biological Products achieved important progress in children's vaccine development, with two vaccines approved for clinical use [3] Market Performance - The vaccine sector saw a 1.33% increase last week, underperforming compared to other pharmaceutical sectors [5][6] - Year-to-date, the vaccine sector has experienced a cumulative decline of 5.12% [6] Valuation Metrics - The vaccine sector's PE (ttm) is 95.41X, with a PB (lf) of 1.87X, indicating a slight increase in valuation metrics compared to previous periods [7] Investment Recommendations - The vaccine industry is under pressure, with a focus on innovation and international expansion as key strategies for recovery [8] - Companies with high technical barriers and differentiated pipelines are recommended for investment, particularly those with strong research and development capabilities [9][28]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

证券研究报告 2025 年 11 月 30 日 湘财证券研究所 行业研究 稀土磁材行业周报 本周轻稀土链价格延续回升，中重稀土价格仍疲软 相关研究： | 《本周行业延续跌势，轻稀土链价格回升》 | | | --- | --- | | 20251123 | | | 《本周行业继续调整，产业链价格短期转 | | | 弱》 | 20251116 | 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -8 -18 50 绝对收益 -11 -17 67 注：相对收益与沪深 300 相比 分析师：王攀 证书编号：S0500520120001 Tel：(8621) 50293524 Email：wangpan2@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼湘财证券研 究所 ◆ 基本面变化。稀土环节，供应端总体呈现偏紧态势，部分分离企业因 检修或原料问题开工率有所下降，导致氧化物现货供应偏紧；金属厂 整体生产稳定，但头部企业散单流出减少，多以长协订单为主，金属 端现货仍有一定支撑。需求端，磁材企业保持较高开工率，国内订单 稳定，同时海外市场需求正逐步恢复， ...

Group 1 - The median return of active quantitative funds for the week of November 24-28, 2025, was 3.02%, outperforming the CSI 300 index at 1.64% and the Wind All A index at 2.90% [3][8] - For the year, the median return of active quantitative funds was 24.89%, compared to 15.04% for the CSI 300 index and 23.57% for the Wind All A index [3][8] - The top-performing active quantitative funds this week had returns between 6% and 8%, with a focus on the computer and electronics sectors [3][8] Group 2 - The "Super Expected Stock Selection Strategy" constructs a stock pool based on net profit exceeding expectations and analyst expectations, using the Wind All A index as the base stock pool [5][14] - For the week of November 24-28, 2025, the selected strategy yielded a return of 3.00%, exceeding the benchmark index by 0.09% [5][16] - For the year, the selected strategy achieved a return of 43.91%, significantly outperforming the benchmark index by 20.34% [5][19] Group 3 - The top 30 selected stocks for November 2025 were concentrated in the machinery sector, with the highest return from Joyoung Co., Ltd. (002242.SZ) at 8.63% [6][20] - The highest-performing active quantitative funds for the year had returns ranging from 58% to 119%, primarily focused on the electronics and machinery sectors [11][12] - The lowest-performing active quantitative funds for the year had returns between -11% and 0%, with a concentration in the food and beverage sector [11][13]

证券研究报告 2025 年 11 月 30 日 湘财证券研究所 行业研究 食品饮料行业周报 茅台理性定调，板块投资信心回暖 相关研究： | 1.《压力逐步释放，耐心等待探 | | | --- | --- | | 底企稳》 | 2025.11.09 | | 2.《10月CPI回暖，消费板块预期 | | | 修复》 | 2025.11.16 | | 3.《板块情绪回暖，低估值极具 | | | 性价比》 | 2025.11.23 | 行业评级：买入（维持） 近十二个月行业表现 | % | 1 个月 | 3 个月 | 12 个月 | | --- | --- | --- | --- | | 相对收益 | 4.8 | -5.0 | -21.0 | | 绝对收益 | 0.8 | -1.8 | -5.2 | 注：相对收益与沪深 300 相比 分析师：李育文 证书编号：S0500523060001 Tel：021-50295328 Email：liyw3@xcsc.com 分析师：张弛 面对市场与渠道，茅台强调以消费者为中心，推动"三个转型、三端变革"， 切实保障市场渠道长期稳定向好、科学研判投放节奏、持续构建"多载体、 多主 ...